Topics

FDA Approves AbbVie’s Mavyret as First Treatment for all Genotypes of Hepatitis C in Pediatric Patients

16:42 EDT 1 May 2019 | Speciality Pharma Journal

The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17. Mavyret was previously approved to treat HCV in adults in 2017. “Direct-acting antiviral drugs reduce the amount of HCV in the body by preventing the virus from …

Original Article: FDA Approves AbbVie’s Mavyret as First Treatment for all Genotypes of Hepatitis C in Pediatric Patients

NEXT ARTICLE

More From BioPortfolio on "FDA Approves AbbVie’s Mavyret as First Treatment for all Genotypes of Hepatitis C in Pediatric Patients"

Quick Search

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...